Prelude Therapeutics Incorporated
PRLD
$4.66
$0.020.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 73.43% | 250.00% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 73.43% | 250.00% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 73.43% | 250.00% | -- | -- | -- |
| SG&A Expenses | -22.33% | -20.08% | -8.45% | -3.37% | -0.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.34% | -10.06% | -0.19% | 6.89% | 10.91% |
| Operating Income | 26.09% | 15.51% | 5.11% | -1.80% | -5.62% |
| Income Before Tax | 21.76% | 15.01% | 4.26% | -1.82% | -4.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.76% | 15.01% | 4.26% | -1.82% | -4.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.76% | 15.01% | 4.26% | -1.82% | -4.38% |
| EBIT | 26.09% | 15.51% | 5.11% | -1.80% | -5.62% |
| EBITDA | 26.38% | 15.80% | 5.35% | -1.47% | -5.21% |
| EPS Basic | 22.58% | 17.09% | 9.10% | 10.57% | 18.15% |
| Normalized Basic EPS | 23.56% | 17.09% | 9.10% | 10.56% | 18.14% |
| EPS Diluted | 22.81% | 17.32% | 9.36% | 10.81% | 17.90% |
| Normalized Diluted EPS | 23.56% | 17.09% | 9.10% | 10.56% | 18.14% |
| Average Basic Shares Outstanding | 1.52% | 2.37% | 5.19% | 12.73% | 25.71% |
| Average Diluted Shares Outstanding | 1.52% | 2.37% | 5.19% | 12.73% | 25.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |